Clinical Cancer Treatment Trials Lead to New Standard of Care for Lung Cancer Patients - NBC 5 Dallas-Fort Worth

Clinical Cancer Treatment Trials Lead to New Standard of Care for Lung Cancer Patients

    processing...

    NEWSLETTERS

    Trials Lead to New Standard of Care for Lung Cancer Patients

    Results from several clinical trials combining chemo and immunotherapy changed the standard of care for many lung cancer patients last year. The chemo kills the cancer cells, and the drug prompts the immune system to do its job. (Published Tuesday, Nov. 19, 2019)

    Results from several clinical trials combining chemo and immunotherapy changed the standard of care for many lung cancer patients last year. The chemo kills the cancer cells, and the drug prompts the immune system to do its job.

    Rider, snowboarder and climber Jim Brown still tears it up on his electronic mountain bike -- sometimes with daughter, Isabella.

    "I'm the last person in the world that people would think would get lung cancer," Brown said. "And it was pretty shocking."

    Carcinogen exposure from Brown's 25-year firefighting career was blamed for his stage 4 adenocarcinoma lung cancer, diagnosed in 2015. He enrolled in Keynote 21, a trial that added Keytruda to standard chemo for some participants. He didn't get the Keytruda, but the chemo kept his disease stable for 22 months.

    Shooting at 2nd Wisconsin High School Leaves Community in Shock

    [NATL] Shooting at 2nd Wisconsin High School Leaves Community in Shock

    A school officer and a student were injured at Wisoonsin's Oshkosh West High School Tuesday morning, when the student was shot after attempting to stab the office with a sharp object. The shooting comes just one day after a school resource officer at Waukesha South High School shot a 17-year-old armed student who refused to drop his weapon.

    (Published Wednesday, Dec. 4, 2019)

    Christina S. Baik MD, MPH, Seattle Cancer Care Alliance at University of Washington School of Medicine helped with the combination drug trial, which became the standard of care for many lung cancer patients last year.

    "All patients who don't have a specific genetic mutation are receiving this drug combination of chemo and pembrolizumab as first treatment," Baik said.

    Brown has a genetic mutation. He entered a trial for lorlatinib, a targeted drug that got FDA approval soon after.

    "It's progression of medicine, and unless people are willing to do clinical trials, we can't move forward," Brown said.

    "This is a mechanism by which patients are getting treatment of tomorrow. I think that's one thing that we like to say here, that you're getting a treatment of tomorrow," Baik said.

    Brown is already in another trial comparing blood markers to CT scans to track disease progression.

    Key Findings of Fact from 'The Trump-Ukraine Impeachment Inquiry Report'

    [NATL] Key Findings of Fact from 'The Trump-Ukraine Impeachment Inquiry Report'

    The House Intelligence Committee released a report outlining evidence for the impeachment of President Donald Trump.

    (Published Wednesday, Dec. 4, 2019)

    Brown is still working in the firehouse. He is passionate about educating other firefighters on how to minimize exposure to carcinogens. Baik said many patients don't benefit from these drug combinations, so there's lots of room for research there.

    Contributors to this news report include: Wendy Chioji, Field Producer; Rusty Reed, Videographer; Cyndy McGrath, Supervising Producer; Roque Correa, Editor.

    Get the latest from NBC DFW anywhere, anytime

    • Download the App

      Available for IOS and Android